Revenue recognition, reserve target exclusivity period Revenue Recognition Reserve Target Exclusivity Period Revenue recognition reserve target exclusivity period. Segment Information Segment Reporting Policy Policy [Text Block] Forecast [Member] Operating expenses: Operating Expenses [Abstract] Loss from operations Operating Income Loss Common stock purchased Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award Contra expense included in research and development expense Contra Expense Included In Research And Development Expense Contra expense included in research and development expense. Vinbiocare [Member] Vinbiocare [Member] Vinbiocare. September 2021 Lease Agreement [Member] September Two Thousand And Twenty One Lease Agreement [Member] September two thousand and twenty one lease agreement. Foreign currency transaction gain Foreign Currency Transaction Gain Loss Realized COVID-19 Vaccine Development C O V I D Nineteen Vaccine Development [Member] COVID-19 vaccine development. Entity Emerging Growth Company Entity Emerging Growth Company Income Tax Disclosure [Abstract] Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expense and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Schedule of Cash and Cash Equivalents and Restricted Cash Schedule Of Cash And Cash Equivalents Table [Text Block] Number of shares available Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Payments to Acquire Property, Plant, and Equipment, Total Acquisition of property and equipment Payments To Acquire Property Plant And Equipment Long-term Debt [Member] Long Term Debt [Member] Deferred Revenue, Noncurrent, Total Deferred revenue, net of current portion Deferred Revenue Noncurrent Geographical Statement Geographical [Axis] Common stock: $0.001 par value; 60,000 shares authorized;; 26,407 issued and outstanding at March 31,2022 and 26,372 issued and outstanding at December 31,2021 Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock Value Entity Address, State or Province Entity Address State Or Province Total liabilities Liabilities Payments for advance Payments For Advance To Affiliate Billing received amount from third party related to clinical trial Billing Received Amount Related to Clinical Trial Billing received amount related to clinical trial. Schedule of Revenue Disaggregation Of Revenue Table [Text Block] Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member] Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member] Collaboration Partner Cure Vac entered into Co-Development Agreement. Royalty payment term description Royalty Payment Term Description Royalty payment term description. Janssen [Member] Janssen [Member] Janssen. Weighted-average shares outstanding, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment and contingencies. Purchase of additional shares of common stock price per share Option To Purchase Of Additional Shares Of Common Stock Price Per Share Option to purchase of additional shares of common stock price per share. General and Administrative [Member] General And Administrative Expense [Member] Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts receivable Accounts Receivable Net Current Contractual term Collaboration Agreement Contractual Term Collaboration agreement contractual term. Deductions for promised services provided in current period Contract With Customer Liability Revenue Recognized Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] us-gaap:OtherLiabilitiesCurrent Other Liabilities, Current Other Liabilities, Current, Total City Area Code City Area Code Upfront fee received Upfront Fee Received Upfront fee received. Debt instrument, collateral Debt Instrument Collateral Liquidity Liquidity Policy Policy [Text Block] Liquidity. Issuance of common stock under equity plans Stock Issued During Period Value Under Equity Plan Stock issued during period value under equity plan. Cash consideration paid for equity interest in joint venture Payments To Acquire Interest In Joint Venture Consideration received for common stock purchase Sale Of Stock Consideration Received Per Transaction Contract with Customer, Liability, Total Deferred revenue Contract Liabilities, Balance Contract Liabilities, Balance Contract With Customer Liability Potential principal repayment of loan Potential Principal Repayments Of Debt Instrument Potential Principal Repayments Of Debt Instrument. Issuance of common stock Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period Shares New Issues Interest of the prime rate plus Debt Instrument Basis Spread On Variable Rate1 Contract Assets, Additions for revenue recognized from billings Contract With Customer Asset Additions For Revenue Recognized Contract with customer asset additions for revenue recognized. Scenario Statement Scenario [Axis] Non-Rare Disease Targets [Member] Non Rare Disease Targets [Member] Non-rare disease targets. Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Cash and cash equivalents, including restricted cash Total cash, cash equivalents and restricted cash shown in the statement of cash flows Cash, cash equivalents and restricted cash at beginning of the period Cash, cash equivalents and restricted cash at end of the period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cystic Fibrosis Foundation [Member] Cystic Fibrosis Foundation Therapeutics Inc [Member] Cystic Fibrosis Foundation Therapeutics, Inc. Related Party Related Party [Domain] Other Noncash Income (Expense), Total Other non-cash expenses Other Noncash Income Expense Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Net cash used in investing activities Net Cash Provided By Used In Investing Activities Debt Debt Disclosure [Text Block] Purchase of property and equipment in accounts payable Capital Expenditures Incurred But Not Yet Paid Israeli Ministry of Health ("MOH") [Member] I L Issuance of common stock to Ultragenyx on option exercise (in shares) Stock Issued During Period Shares Option Exercised Stock issued during period shares option exercised. Payments for matching funds for remaining budgeted costs Payments For Matching Funds For Remaining Budgeted Costs Payments for matching funds for remaining budgeted costs. Employee-related Liabilities, Current, Total Accrued compensation Employee Related Liabilities Current General and Administrative Expense, Total General and administrative General And Administrative Expense Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property and equipment, net Property and equipment, net Property Plant And Equipment Net Common stock, shares issued Issuance of Shares Common Stock, Shares, Issued, Total Purchase of common stock, shares Interest Expense, Long-term Debt, Total Interest expense related to long-term debt Interest Expense Long Term Debt Statement Of Income And Comprehensive Income [Abstract] Tenant improvement allowance Payments For Proceeds From Tenant Allowance Singapore Economic Development Board [Member] S G Operating lease right-of-use asset, net Operating Lease Right Of Use Asset Security Exchange Name Security Exchange Name Comprehensive loss: Comprehensive Income Net Of Tax [Abstract] Statistical Measurement Range [Member] Office equipment and furniture [Member] Furniture And Fixtures [Member] February 2020 Lease Agreement [Member] February Two Thousand And Twenty Lease Agreement [Member] February two thousand and twenty lease agreement. Revenue. Revenue [Line Items] Revenue [Line Items] Other Liabilities, Noncurrent, Total Other long-term liabilities Other Liabilities Noncurrent Subsequent Event Type Subsequent Event Type [Domain] Debt Disclosure [Abstract] Option exercise revenue range per target Option Exercise Revenue Range Per Target Option exercise revenue range per target. Document Period End Date Document Period End Date Non-current restricted cash Non-current restricted cash Restricted Cash Noncurrent Income Statement Location Income Statement Location [Axis] Disbursement Due July 2020 [Member] Disbursement Period Three [Member] Disbursement period three. Total Accrued liabilities Accrued Liabilities Current Research Collaboration And Exclusive License Agreement [Member] Research Collaboration And Exclusive License Agreement [Member] Research Collaboration and Exclusive License Agreement. Common stock, shares authorized Common Stock Shares Authorized Transaction price Collaboration Agreement Transaction Price Collaboration agreement transaction price. Current portion of operating lease liability Operating Lease Liability Current Related Party Related Party Transactions By Related Party [Axis] Contract with Customer, Asset, after Allowance for Credit Loss, Total Contract Assets, Balance Contract Assets, Balance Contract With Customer Asset Net Issuance of common stock to Ultragenyx on option exercise Stock Issued During Period Value Option Exercised Stock issued during period value option exercised. Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Balance Sheet Related Disclosures [Abstract] Remaining Lessee Operating Lease Liability Payments Due After Year Four Lessee operating lease liability payments due after year four. Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Antidilutive securities excluded from computation of earnings per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Maximum discounted purchase price Share Based Compensation Arrangement By Share Based Payment Award Maximum Discounted Purchase Price Share-based compensation arrangement by share-based payment award, maximum discounted purchase price. Debt Instrument [Table] Debt Instrument [Table] Loan maturity date Debt Instrument Maturity Date Number of shares owned Investment Owned Balance Shares Maximum LUNAR-COVID 19 sales required for Loans forgivable Maximum Sales Required For Loans Forgivable Maximum sales required for loans forgivable . Cash paid for interest Interest Paid Net Loan and Security Agreement [Member] Loan And Security Agreement [Member] Loan and security agreement. Entity Address, Address Line Two Entity Address Address Line2 Current Fiscal Year End Date Current Fiscal Year End Date NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Statement of Cash Flows Inventory Cash Flow Policy Remaining research period Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 Operating lease costs Operating Lease Cost Prepayment fee percentage Prepayment Fee Percentage Prepayment fee percentage. Option exercise fee received Option Exercise Fee Revenue Received Option exercise fee revenue received. Equity method ownership percentage Equity Method Investment Ownership Percentage Adjustments to transaction price Adjustments To Transaction Price Adjustments to transaction price. Disaggregation Of Revenue [Table] Disaggregation Of Revenue [Table] Counterparty Name Counterparty Name [Axis] Assets Assets [Abstract] Contract Assets, Deductions for cash collections Contract With Customer Asset Deductions For Cash Collections Contract with customer asset deductions for cash collections. Lessee Operating Lease Liability Payments Due Next Twelve Months, Total 2023 Lessee Operating Lease Liability Payments Due Next Twelve Months Accounts Payable, Current, Total Accounts payable Accounts Payable Current Ultragenyx [Member] Ultragenyx [Member] Ultragenyx. Term loan Debt Instrument Face Amount Common stock, par value Common Stock Par Or Stated Value Per Share Development and option agreement date Development And Option Agreement Date Development and option agreement date. Investment, Name Schedule Of Equity Method Investment Equity Method Investee Name [Axis] Balance (in shares) Balance (in shares) Shares Outstanding Contra expense remaining amount included in accrued expenses Contra Expense Remaining Amount Included In Accrued Expenses Contra expense remaining amount included in accrued expenses. Stockholders Equity Note [Abstract] Research and Development, Net Research And Development Expense Policy Document Type Document Type Revenue, practical expedient description Revenue Practical Expedient Remaining Performance Obligation Description Operating lease liability, net of current portion Operating Lease Liability Noncurrent Schedule of Accrued Liabilities Schedule Of Accrued Liabilities Table [Text Block] Total current assets Assets Current Disaggregation Of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Stock Option [Member] Employee Stock Option [Member] Clinical accruals Clinical Accruals Current Clinical accruals current. Long-term Debt, Type Longterm Debt Type [Domain] October 2017 Lease Amendment [Member] October Two Thousand And Seventeen Lease Amendment [Member] October 2017 lease amendment. Investment in joint venture Equity Method Investment Aggregate Cost Equity Method Investment, Nonconsolidated Investee Equity Method Investment Nonconsolidated Investee [Axis] Income Tax Expense (Benefit), Total Income tax expense Income Tax Expense Benefit Non-cash investing activities Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Summary Of Significant Accounting Policy [Line Items] Summary Of Significant Accounting Policy [Line Items] Summary of significant accounting policy. Earnings Per Share, Basic and Diluted, Total Net loss per share, basic and diluted Earnings Per Share Basic And Diluted Leases [Abstract] Western Alliance Bank [Member] Western Alliance Bank [Member] Western Alliance Bank. Purchase of additional shares of common stock Option To Purchase Of Additional Shares Of Common Stock Option to purchase of additional shares of common stock. Disbursement Due April 2020 [Member] Disbursement Period Two [Member] Disbursement period two. Other [Member] Other [Member] Other. Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, shares outstanding Common Stock Shares Outstanding Plan Name Plan Name [Axis] Underwritten Public Offering [Member] Underwritten Public Offering [Member] Underwritten public offering. Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Less accumulated depreciation and amortization Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Revenue Recognition Revenue Recognition Policy [Text Block] Total operating expenses Operating Expenses Rare Disease Targets [Member] Rare Disease Targets [Member] Rare disease targets. OPERATING ACTIVITIES: Net Cash Provided By Used In Operating Activities [Abstract] Revenue recognition potential milestone revenue recognized Revenue Recognition Potential Milestone Revenue Recognized Revenue recognition potential milestone revenue recognized. Acquired in-process research and development expense Non-cash charge recorded in acquired in-process research and development expense Research And Development In Process 2021 Inducement Equity Incentive Plan [Member] Twenty Twenty One Inducement Equity Incentive Plan [Member] 2021 Inducement equity incentive plan. Remaining Payments of Operating Lease Liability Lessee Operating Lease Liability Maturity Table [Text Block] 2024 Lessee Operating Lease Liability Payments Due Year Two Loan first principal payment extended maturity date Debt Instrument Date Of First Required Payment1 Net loss Net loss Net Income Loss Description of Business, Basis of Presentation and Summary of Significant Accounting Policies Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Text Block] Weighted-average discount rate Operating Lease Weighted Average Discount Rate Percent Research and Development [Member] Research And Development Expense [Member] Document Fiscal Period Focus Document Fiscal Period Focus Accounting Policies [Abstract] Entity Address, Address Line One Entity Address Address Line1 Grant awarded Grants Receivable Potential target license term Potential Target License Term Potential target license term. Percentage of owned shares Investment Owned Percent Of Net Assets Total current liabilities Liabilities Current Entity Address, Postal Zip Code Entity Address Postal Zip Code Number of reserved vaccine doses Number Of Reserved Vaccine Doses Number of reserved vaccine doses. Pre-Launch Inventory Pre Launch Inventory Policy Policy [Text Block] Pre-launch inventory policy. Total remaining lease payments Lessee Operating Lease Liability Payments Due Product and Service Products And Services [Domain] Takeda Pharmaceutical Company Limited [Member] Takeda Pharmaceutical Company Limited And Providence Therapeutics Incorporation [Member] Takeda Pharmaceutical Company Limited and Providence Therapeutics Incorporation. Research equipment [Member] Equipment [Member] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Net cash used in operating activities Net Cash Provided By Used In Operating Activities Upfront payment received Upfront Payment Received Upfront payment received. Common Stock [Member] Statement Equity Components [Axis] Proceeds from Issuance of Long-term Debt, Total Proceeds from long-term debt agreement Proceeds From Issuance Of Long Term Debt Current assets: Assets Current [Abstract] Entity Registrant Name Entity Registrant Name Revenue. Revenue [Table] Revenue [Table] Consideration received Collaboration Agreement Consideration Received Collaboration agreement consideration received. Debt instrument, collateral amount Debt Instrument Collateral Amount Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] ADAIR Technology [Member] A D A I R Technology [Member] ADAIR Technology. Entity Interactive Data Current Entity Interactive Data Current February 2021 Lease Agreement [Member] February Two Thousand And Twenty One Lease Agreement [Member] February two thousand and twenty one lease agreement. Entity Address, City or Town Entity Address City Or Town Contra research and development expense recognized Contra Research And Development Expense Contra research and development expense. Research Collaboration And Exclusive License Agreement [Member] Research Collaboration And License Agreement [Member] Research collaboration and license agreement. 2022 Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year Number of performance obligations Number Of Performance Obligations Number of performance obligations. Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Trading Symbol Trading Symbol Related Party Transactions Related Party Transactions Disclosure [Text Block] INVESTING ACTIVITIES: Net Cash Provided By Used In Investing Activities [Abstract] Less: imputed interest Lessee Operating Lease Liability Undiscounted Excess Amount Local Phone Number Local Phone Number Total stockholders’ equity Balance Balance Stockholders Equity Subsequent Event Type Subsequent Event Type [Axis] Amount agreed to fund Agreement Amount Agreed To Fund Agreement amount agreed to fund. Statistical Measurement Range [Axis] Entity Small Business Entity Small Business Leases Lessee Leases Policy [Text Block] Share price Share Price APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Share-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Long-term Debt, Excluding Current Maturities, Total Long-term debt, net of current portion Long Term Debt Noncurrent Grant 1 Grant One [Member] Grant one. Accrued Liabilities Current [Abstract] Deferred Revenue, Current, Total Deferred revenue Deferred Revenue Current Number of targets Number Of Reserve Targets Number of reserve targets. CureVac [Member] Cure Vac A G [Member] CureVac AG. ASC 606 [Member] Accounting Standards Update201409 [Member] Alexion [Member] Alexion Pharmaceuticals Inc [Member] Alexion Pharmaceuticals, Inc. Additional Paid in Capital, Ending Balance Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Total Additional paid-in capital Additional Paid In Capital Upfront fee/consideration Upfront Fee And Consideration Upfront fee/consideration. Vallon Pharmaceuticals, Inc. [Member] Vallon Pharmaceuticals Inc [Member] Vallon Pharmaceuticals, Inc. Sale of Stock Sale Of Stock Name Of Transaction [Domain] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Revenue From Contract With Customer [Abstract] Plan Name Plan Name [Domain] Class Of Stock [Line Items] Class Of Stock [Line Items] 2023 Long Term Debt Maturities Repayments Of Principal In Next Twelve Months Warrant fee payable Warrant Fee Payable Warrant fee payable. Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums, Total Loan origination fee paid Unamortized Loan Commitment And Origination Fees And Unamortized Discounts Or Premiums Lessee, operating lease, term of contract Lessee Operating Lease Term Of Contract Monthly base rent Monthly Base Rent Monthly base rent. Issuance of common stock, net of issuance costs Stock Issued During Period Value New Issues Lack of marketability discount restricted period Lack Of Marketability Discount Restricted Period Lack of marketability discount restricted period. Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis] Other accrued research and development expenses Other Accrued Research And Development Expenses Other accrued research and development expenses. Common stock issued, value Stock Issued During Period Value Issued For Services Gain from foreign currency Foreign currency transaction gain Foreign Currency Transaction Gain (Loss), before Tax, Total Foreign Currency Transaction Gain Loss Before Tax Share-based Payment Arrangement, Noncash Expense, Total Share-based compensation expense Share Based Compensation Percentage required to be maintain in consolidated, unrestricted cash Percentage Required To Be Maintained In Consolidated Unrestricted Cash Percentage required to be maintained in consolidated unrestricted cash. Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Related Party Transactions [Abstract] Maximum discounted amount per year Share Based Compensation Arrangement By Share Based Payment Award Maximum Discounted Amount Share based compensation arrangement by share based payment award maximum discounted amount. Long-term Debt, Current Maturities, Total Current portion of long-term debt Long Term Debt Current Disbursement Due October 2020 [Member] Disbursement Period Four [Member] Disbursement period four. Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Commitments And Contingencies Disclosure [Abstract] Right-of-use asset obtained in exchange for lease liabilities Right Of Use Asset Obtained In Exchange For Operating Lease Liability Total assets Assets Issuance of common stock upon exercise of stock options (in shares) Stock Issued During Period Shares Stock Options Exercised Statement [Line Items] Statement [Line Items] Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Document Quarterly Report Document Quarterly Report Property Plant And Equipment [Abstract] Dividends, Total Dividends declared or paid Dividends Statement Of Cash Flows [Abstract] Additional Paid-In Capital [Member] Additional Paid In Capital [Member] Title of 12(b) Security Security12b Title Comprehensive loss Comprehensive Income Net Of Tax 2020 Employee Stock Purchase Plan [Member] Two Thousand Twenty Employee Stock Purchase Plan [Member] Two Thousand Twenty Employee Stock Purchase Plan. Debt Instrument [Line Items] Debt Instrument [Line Items] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Summary of Components of Property and Equipment, Net Property Plant And Equipment [Text Block] Percentage of equity interest in joint venture Percentage Of Equity Interest In Joint Venture Percentage of equity interest in joint venture. Schedule of Maturities of Long-term Debt Schedule Of Maturities Of Long Term Debt Table [Text Block] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Vinbiocare Agreement [Member] Vinbiocare Agreement [Member] Vinbiocare agreement. Entity Current Reporting Status Entity Current Reporting Status Revenue Revenue From Contract With Customer [Text Block] Remaining performance obligation Revenue Remaining Performance Obligation Scenario Scenario Unspecified [Domain] Investment, Name Equity Method Investee Name [Domain] Accrued interest added to principal debt balance Debt Instrument, Increase, Accrued Interest Lessee, operating leases, option to extend Lessee Operating Lease Option To Extend Net Loss per Share Earnings Per Share Policy [Text Block] LUNAR-CF [Member] L U N A R C F [Member] LUNAR-CF. 2022 Lessee Operating Lease Liability Payments Remainder Of Fiscal Year Proceeds from debt Net increase in indebtedness Proceeds From Issuance Of Debt Computer and software [Member] Computer Equipment [Member] Term loan draw down Borrowings Under Guaranteed Investment Agreements Reduction in number of common stock shares available for future issuance Reduction in Number of Common Stock Capital Shares Available for Future Issuance Reduction in number of common stock capital shares available for future issuance. Long-term Debt, Type Longterm Debt Type [Axis] Income Statement Location Income Statement Location [Domain] Increase (Decrease) in Accrued Liabilities, Total Accrued liabilities Increase Decrease In Accrued Liabilities Minimum [Member] Minimum [Member] 2019 Omnibus Equity Incentive Plan [Member] Two Thousand Nineteen Omnibus Incentive Plan [Member] Two thousand nineteen omnibus incentive plan. Pharmaceutical Company [Member] Pharmaceutical Company [Member] Pharmaceutical company. Security deposit Security Deposit Issuance of common stock upon exercise of stock options Stock Issued During Period Value Stock Options Exercised FINANCING ACTIVITIES: Net Cash Provided By Used In Financing Activities [Abstract] Entity Filer Category Entity Filer Category Document Fiscal Year Focus Document Fiscal Year Focus Construction in progress [Member] Construction In Progress [Member] Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Accumulated deficit Accumulated deficit Retained Earnings Accumulated Deficit Income Taxes Income Tax Disclosure [Text Block] Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Depreciation And Amortization Fair Value Disclosures [Abstract] Nonrefundable upfront payment received Nonrefundable Upfront Payment Received Nonrefundable upfront payment received. Maximum [Member] Maximum [Member] Summary of Changes in Balances of Contract Assets and Contract Liability Contract With Customer Asset And Liability Table [Text Block] Entity Central Index Key Entity Central Index Key Issuance of common stock related to acquired in-process research and development Stock Issued During Period Value Acquisitions Received first installment Payment Received First Installment Payment received first installment. Entity Tax Identification Number Entity Tax Identification Number Equity Component Equity Component [Domain] Final payment of disbursement amount Final Payment Of Disbursement Amount Final payment of disbursement amount. Option to extend initial term on an annual basis Option To Extend Initial Term On An Annual Basis Option to extend initial term on an annual basis. Accounts receivable Increase Decrease In Accounts Receivable Leasehold improvements [Member] Leasehold Improvements [Member] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment and contingencies. Share-based compensation number of shares authorized Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Statement [Table] Statement [Table] Weighted-average remaining lease term Operating Lease Weighted Average Remaining Lease Term1 Entity File Number Entity File Number Non-refundable payment received Non Refundable Payment Received Non-refundable payment received. Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] mRNA Technology [Member] M R N A Technology [Member] mRNA technology. Accumulated Deficit [Member] Retained Earnings [Member] Accounting Standards Update Type Of Adoption [Member] Accounting Standards Update Adjustments For New Accounting Pronouncements [Axis] Revenue from Contract with Customer, Excluding Assessed Tax, Total Total revenue Revenue Revenue From Contract With Customer Excluding Assessed Tax Increase (Decrease) in Accounts Payable, Total Accounts payable Increase Decrease In Accounts Payable Current liabilities: Liabilities Current [Abstract] Share-Based Compensation Expense Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Subsequent Events [Member] Subsequent Event [Member] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Operating Lease, Liability, Total Total operating lease liabilities Operating Lease Liability Common Stock [Member] Common Stock [Member] Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Property and equipment, gross Property Plant And Equipment Gross Schedule Of Summary Of Significant Accounting Policies [Table] Schedule Of Summary Of Significant Accounting Policies [Table] Schedule of summary of significant accounting policies. Cover [Abstract] Prepaid expenses and other current assets Prepaid Expenses And Other Receivables The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and loans receivable. Expiration of initial term Expiration Of Intial Term Expiration of initial term. Statement Of Stockholders Equity [Abstract] Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Number of operating segment for research and development Number Of Operating Segments Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Equity Method Investment, Nonconsolidated Investee Equity Method Investment Nonconsolidated Investee [Domain] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Document Transition Report Document Transition Report Royalty payment percentage of proceeds from net sales Royalty Payment Percentage Royalty payment percentage. Proceeds from exercise of stock options Proceeds From Stock Options Exercised Operating lease extended additional term Lessee Operating Lease Renewal Term Disbursed amount upon execution of amendment Disbursed Amount Upon Execution Of Amendment Disbursed amount upon execution of amendment. Research and Development Expense, Total Research and development, net Research And Development Expense Underlying Agreement [Member] Underlying Agreement [Member] Underlying agreement. Issuance of common stock related to acquired in-process research and development (in shares) Stock Issued During Period Shares Acquisitions Loan interest-only payment extended maturity date Debt Instrument Interest Only Payment Extended Maturity Date Debt instrument interest only payment extended maturity date. Share-based compensation expenses Share-based compensation expenses Allocated Share Based Compensation Expense Joint Ventures, Equity Method Investments and Variable Interest Entities Joint Ventures Equity Method Investments And Variable Interest Entities Policy [Text Block] Joint ventures, equity method investments and variable interest entities. Issuance of common stock under equity plans (in shares) Stock Issued During Period Shares Under Equity Plan Stock issued during period shares under equity plan. Statement Of Financial Position [Abstract] Lease Contractual Term Lease Contractual Term [Axis] Stockholders’ equity Stockholders Equity [Abstract] Lease Contractual Term Lease Contractual Term [Domain] Disbursement payment upon achievement of required manufacturing practices and IND application Disbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D Application Disbursement payment upon achievement of required manufacturing practices and IND application. Equity-method investment Equity Method Investments Changes in operating assets and liabilities Increase Decrease In Operating Capital [Abstract] 2025 Lessee Operating Lease Liability Payments Due Year Three Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Common stock reserved for future issuance Common Stock Capital Shares Reserved For Future Issuance Award Type Award Type [Axis] Entity Shell Company Entity Shell Company Liabilities and stockholders’ equity Liabilities And Stockholders Equity [Abstract] Loan accrues interest rate per annum, percentage Debt Instrument Interest Rate Effective Percentage Entity Incorporation, State or Country Code Entity Incorporation State Country Code Contract Liabilities, Additions for advanced billings Contract With Customer Liability Additions For Advanced Billings Contract With Customer Liability Additions For Advanced Billings Counterparty Name Repurchase Agreement Counterparty Name [Domain] Acquisition of in-process research and development through issuance of common stock Acquisition Of Research And Development In Process Through Issuance Of Common Stock Acquisition of research and development in process through issuance of common stock. Grant, number of installments Grant Receivable Number Of Installments Grant receivable number of installments. Disbursement Due January 2020 [Member] Disbursement Period One [Member] Disbursement period one. Amendment Flag Amendment Flag Disbursement amount payable upon achievement of project goal Disbursement Amount Payable Upon Achievement Of Project Goal Disbursement amount payable upon achievement of project goal. Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Product and Service Product Or Service [Axis] Other Nonoperating Income (Expense), Total Finance expense, net Other Nonoperating Income Expense Deferred revenue Increase Decrease In Contract With Customer Liability Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Loss (gain) from equity-method investment Income (Loss) from Equity Method Investments, Total (Loss) gain from equity-method investment Income Loss From Equity Method Investments Operating Lease Liability Current Statement Of Financial Position [Extensible List] Operating Lease Liability Current Statement Of Financial Position [Extensible List] Grant 2 Grant Two [Member] Grant two. Extension to interest only period Debt Instrument Interest Only Payment Extended Period Debt instrument interest only payment extended period. Total Long-term debt Long Term Debt Cystic Fibrosis Foundation Liability (Note 9) Accrued Cystic Fibrosis Foundation Liability Accrued cystic fibrosis foundation liability. Axcelead, Inc [Member] Axcelead Inc [Member] Axcelead, Inc. Other Collaboration Agreements [Member] Other Collaboration Agreements [Member] Other collaboration agreements. Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Geographical Segment Geographical [Domain] Sale of Stock Subsidiary Sale Of Stock [Axis] Schedule of Share-based Compensation Expenses Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Proceeds from issuance of common stock, net of issuance costs Proceeds From Issuance Of Common Stock